Across TCGA pan-cancer cohorts, TBC1D3P2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TBC1D3P2 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TBC1D3P2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TBC1D3P2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD and UCEC are the cancer types where TBC1D3P2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.199	0.711	<.001	15	view →
UCEC	DFS	Median	All	0.959	0.633	.034	8	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: TBC1D3P2 tumor-vs-normal RNA expression · all TBC1D3P2 data types